Update on Paraneoplastic and Autoimmune Disorders of the Central Nervous System

ABSTRACT

Although the discovery of antineuronal antibodies has facilitated the diagnosis of paraneoplastic neurologic disorders, the recognition and treatment of these disorders remain a challenge. Some antibodies are more syndrome-specific than others, and some syndromes suggest a paraneoplastic etiology more frequently than others. Because some antineuronal antibodies may occur in cancer patients without paraneoplastic neurologic disorders, their detection does not necessarily imply that a neurologic disorder is paraneoplastic. Moreover, there is an emerging group of encephalitides that appear to be mediated by antibodies against cell surface or synaptic proteins, may occur with or without tumor association, and are responsive to treatment. This review analyzes the immune responses associated with paraneoplastic and nonparaneoplastic disorders of the central nervous system, and the main clinical features and response to treatment.

Paraneoplastic - neurologic - syndromes - antineuronal - synaptic autoimmunity

REFERENCES

• 1 Dalmau J, Rosenfeld M R. Paraneoplastic syndromes of the CNS.  Lancet Neurol. 2008;  7(4) 327-340
• 2 Graus F, Delattre J Y, Antoine J C et al.. Recommended diagnostic criteria for paraneoplastic neurological syndromes.  J Neurol Neurosurg Psychiatry. 2004;  75(8) 1135-1140
• 3 Ances B M, Vitaliani R, Taylor R A et al.. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates.  Brain. 2005;  128(Pt 8) 1764-1777
• 4 Bataller L, Kleopa K A, Wu G F, Rossi J E, Rosenfeld M R, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes.  J Neurol Neurosurg Psychiatry. 2007;  78(4) 381-385
• 5 Tüzün E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment.  Neurologist. 2007;  13(5) 261-271
• 6 Posner J B. Neurologic Complications of Cancer. Philadelphia; F.A.Davis Company 1995
• 7 Graus F, Bonaventura I, Uchuya M et al.. Indolent anti-Hu-associated paraneoplastic sensory neuropathy.  Neurology. 1994;  44(12) 2258-2261
• 8 Geschwind M D, Tan K M, Lennon V A et al.. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease.  Arch Neurol. 2008;  65(10) 1341-1346
• 9 Psimaras D, Carpentier A F, Rossi C. PNS Euronetwork . Cerebrospinal fluid study in paraneoplastic syndromes.  J Neurol Neurosurg Psychiatry. 2010;  81(1) 42-45
• 10 Dalmau J, Tüzün E, Wu H Y et al.. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.  Ann Neurol. 2007;  61(1) 25-36
• 11 Florance N R, Davis R L, Lam C et al.. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.  Ann Neurol. 2009;  66(1) 11-18
• 12 Dadparvar S, Anderson G S, Bhargava P et al.. Paraneoplastic encephalitis associated with cystic teratoma is detected by fluorodeoxyglucose positron emission tomography with negative magnetic resonance image findings.  Clin Nucl Med. 2003;  28(11) 893-896
• 13 Scheid R, Lincke T, Voltz R, von Cramon D Y, Sabri O. Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis.  Arch Neurol. 2004;  61(11) 1785-1789
• 14 Henson R A, Urich H E. Cancer and the Nervous System: The Neurological Manifestations of Systemic Malignant Disease. London, United Kingdom; Blackwell Scientific 1982
• 15 Bernal F, Graus F, Pifarré A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis.  Acta Neuropathol. 2002;  103(5) 509-515
• 16 Blumenthal D T, Salzman K L, Digre K B, Jensen R L, Dunson W A, Dalmau J. Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis.  Neurology. 2006;  67(1) 146-149
• 17 Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS.  J Neurol. 2010;  257(4) 509-517
• 18 Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre A O, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.  Neurology. 2008;  70(12) 924-928
• 19 Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau J, Graus F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer.  J Neuroimmunol. 2008;  201–202 163-165
• 20 Bataller L, Wade D F, Graus F, Stacey H D, Rosenfeld M R, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.  Neurology. 2004;  62(5) 778-782
• 21 Titulaer M J, Klooster R, Potman M et al.. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.  J Clin Oncol. 2009;  27(26) 4260-4267
• 22 Lancaster E, Lai M, Peng X et al.. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.  Lancet Neurol. 2010;  9(1) 67-76
• 23 Saiz A, Blanco Y, Sabater L et al.. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.  Brain. 2008;  131(Pt 10) 2553-2563
• 24 Blanc F, Ruppert E, Kleitz C et al.. Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?.  J Neurol Sci. 2009;  287(1-2) 69-71
• 25 Tüzün E, Rossi J E, Karner S F, Centurion A F, Dalmau J. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis.  J Neuroimmunol. 2007;  186(1-2) 177-180
• 26 Zuliani L, Sabater L, Saiz A, Baiges J J, Giometto B, Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia.  Neurology. 2007;  68(3) 239-240
• 27 Thieben M J, Lennon V A, Boeve B F, Aksamit A J, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody.  Neurology. 2004;  62(7) 1177-1182
• 28 Dalmau J, Gleichman A J, Hughes E G et al.. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.  Lancet Neurol. 2008;  7(12) 1091-1098
• 29 Lai M, Hughes E G, Peng X et al.. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location.  Ann Neurol. 2009;  65(4) 424-434
• 30 Hutchinson M, Waters P, McHugh J et al.. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody.  Neurology. 2008;  71(16) 1291-1292
• 31 O'Neill J H, Murray N M, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases.  Brain. 1988;  111(Pt 3) 577-596
• 32 Mason W P, Graus F, Lang B et al.. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.  Brain. 1997;  120(Pt 8) 1279-1300
• 33 Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.  Neurology. 2002;  59(5) 764-766
• 34 Fukuda T, Motomura M, Nakao Y et al.. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.  Ann Neurol. 2003;  53(1) 21-28
• 35 Sillevis Smitt P, Kinoshita A, De Leeuw B et al.. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.  N Engl J Med. 2000;  342(1) 21-27
• 36 Younes-Mhenni S, Janier M F, Cinotti L et al.. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.  Brain. 2004;  127(Pt 10) 2331-2338
• 37 Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.  Neurology. 2004;  63(2) 282-286
• 38 Mathew R M, Cohen A B, Galetta S L, Alavi A, Dalmau J. Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET.  J Neurol Sci. 2006;  250(1-2) 153-155
• 39 Mathew R M, Vandenberghe R, Garcia-Merino A et al.. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis.  Neurology. 2007;  68(12) 900-905
• 40 Ritzenthaler T, Verret J M, Honnorat J. [Paraneoplastic chorea and behavioral disorders in a patient with anti-CV2/CRMP5 antibodies and two different tumors].  Rev Neurol (Paris). 2010;  166(1) 90-95
• 41 Zawacki T, Friedman J H, Grace J, Shetty N. Cerebellar toxicity of cytosine arabinoside: clinical and neuropsychological signs.  Neurology. 2000;  55(8) 1234
• 42 Engel P A, Grunnet M, Jacobs B. Wernicke-Korsakoff syndrome complicating T-cell lymphoma: unusual or unrecognized?.  South Med J. 1991;  84(2) 253-256
• 43 Shams'ili S, Grefkens J, de Leeuw B et al.. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.  Brain. 2003;  126(Pt 6) 1409-1418
• 44 Gultekin S H, Rosenfeld M R, Voltz R, Eichen J, Posner J B, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.  Brain. 2000;  123(Pt 7) 1481-1494
• 45 Fakhoury T, Abou-Khalil B, Kessler R M. Limbic encephalitis and hyperactive foci on PET scan.  Seizure. 1999;  8(7) 427-431
• 46 Lawn N D, Westmoreland B F, Kiely M J, Lennon V A, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis.  Mayo Clin Proc. 2003;  78(11) 1363-1368
• 47 Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre J Y. Limbic encephalitis and small cell lung cancer. Clinical and immunological features.  Brain. 1997;  120(Pt 6) 923-928
• 48 Dalmau J, Graus F, Villarejo A et al.. Clinical analysis of anti-Ma2-associated encephalitis.  Brain. 2004;  127(Pt 8) 1831-1844
• 49 Honnorat J, Cartalat-Carel S, Ricard D et al.. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.  J Neurol Neurosurg Psychiatry. 2009;  80(4) 412-416
• 50 Graus F, Saiz A, Lai M et al.. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations.  Neurology. 2008;  71(12) 930-936
• 51 Whitley R J. Herpes simplex encephalitis: adolescents and adults.  Antiviral Res. 2006;  71(2-3) 141-148
• 52 Seeley W W, Marty F M, Holmes T M et al.. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6.  Neurology. 2007;  69(2) 156-165
• 53 Wainwright M S, Martin P L, Morse R P et al.. Human herpesvirus 6 limbic encephalitis after stem cell transplantation.  Ann Neurol. 2001;  50(5) 612-619
• 54 Baloh R W, DeRossett S E, Cloughesy T F et al.. Novel brainstem syndrome associated with prostate carcinoma.  Neurology. 1993;  43(12) 2591-2596
• 55 Saiz A, Bruna J, Stourac P et al.. Anti-Hu-associated brainstem encephalitis.  J Neurol Neurosurg Psychiatry. 2009;  80(4) 404-407
• 56 Matsumoto L, Yamamoto T, Higashihara M et al.. Severe hypokinesis caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasm of the testes.  Mov Disord. 2007;  22(5) 728-731
• 57 Gállego Pérez-Larraya J, Dalmau J. [Classic paraneoplastic syndromes: diagnostic and treatment approach].  Neurologia. 2008;  23(7) 441-448
• 58 Castle J, Sakonju A, Dalmau J, Newman-Toker D E. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease.  Nat Clin Pract Neurol. 2006;  2(10) 566-572, quiz 573
• 59 Vernino S, Tuite P, Adler C H et al.. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma.  Ann Neurol. 2002;  51(5) 625-630
• 60 Forsyth P A, Dalmau J, Graus F, Cwik V, Rosenblum M K, Posner J B. Motor neuron syndromes in cancer patients.  Ann Neurol. 1997;  41(6) 722-730
• 61 Vernino S. Antibody testing as a diagnostic tool in autonomic disorders.  Clin Auton Res. 2009;  19(1) 13-19
• 62 Lennon V A, Ermilov L G, Szurszewski J H, Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease.  J Clin Invest. 2003;  111(6) 907-913
• 63 Iodice V, Kimpinski K, Vernino S, Sandroni P, Fealey R D, Low P A. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy.  Neurology. 2009;  72(23) 2002-2008
• 64 Camdessanché J P, Antoine J C, Honnorat J et al.. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients.  Brain. 2002;  125(Pt 1) 166-175
• 65 Molinuevo J L, Graus F, Serrano C, Reñe R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy.  Ann Neurol. 1998;  44(6) 976-980
• 66 Antoine J C, Honnorat J, Camdessanché J P et al.. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.  Ann Neurol. 2001;  49(2) 214-221
• 67 Yu Z, Kryzer T J, Griesmann G E, Kim K, Benarroch E E, Lennon V A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.  Ann Neurol. 2001;  49(2) 146-154
• 68 de Seze J, Devos D, Castelnovo G et al.. The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis.  Neurology. 2001;  57(8) 1359-1363
• 69 Bataller L, Graus F, Saiz A, Vilchez J J. Spanish Opsoclonus-Myoclonus Study Group . Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.  Brain. 2001;  124(Pt 2) 437-443
• 70 Bataller L, Rosenfeld M R, Graus F, Vilchez J J, Cheung N K, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome.  Ann Neurol. 2003;  53(3) 347-353
• 71 Matthay K K, Blaes F, Hero B et al.. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.  Cancer Lett. 2005;  228(1-2) 275-282
• 72 Pranzatelli M R, Tate E D, Travelstead A L et al.. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.  J Pediatr Hematol Oncol. 2006;  28(9) 585-593
• 73 Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome.  Eur J Pediatr. 2007;  166(4) 359-363
• 74 Pranzatelli M R, Tate E D, Dukart W S, Flint M J, Hoffman M T, Oksa A E. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone.  J Pediatr. 2005;  147(3) 372-378
• 75 Vincent A, Buckley C, Schott J M et al.. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.  Brain. 2004;  127(Pt 3) 701-712
• 76 Iranzo A, Graus F, Clover L et al.. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis.  Ann Neurol. 2006;  59(1) 178-181
• 77 Jarius S, Hoffmann L, Clover L, Vincent A, Voltz R. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis.  J Neurol Sci. 2008;  268(1-2) 74-77
• 78 Tan K M, Lennon V A, Klein C J, Boeve B F, Pittock S J. Clinical spectrum of voltage-gated potassium channel autoimmunity.  Neurology. 2008;  70(20) 1883-1890
• 79 Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis.  Ann Neurol. 2003;  54(4) 530-533
• 80 Reid J M, Foley P, Willison H J. Voltage-gated potassium channel-associated limbic encephalitis in the West of Scotland: case reports and literature review.  Scott Med J. 2009;  54(4) 27-31
• 81 Vincent A. Antibodies to contactin-associated protein 2 (CASPR2) in thymoma and Morvan's syndrome.  Ann Neurol. 2009;  66(suppl 13) S3
• 82 Graus F, Boronat A, Xifró X et al.. The expanding clinical profile of anti-AMPA receptor encephalitis.  Neurology. 2010;  74(10) 857-859
• 83 Matà S, Muscas G C, Naldi I et al.. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies.  J Neuroimmunol. 2008;  199(1-2) 155-159
• 84 Gable M S, Gavali S, Radner A et al.. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis.  Eur J Clin Microbiol Infect Dis. 2009;  28(12) 1421-1429
• 85 Sansing L H, Tüzün E, Ko M W, Baccon J, Lynch D R, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies.  Nat Clin Pract Neurol. 2007;  3(5) 291-296
• 86 Dale R C, Irani S R, Brilot F et al.. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica.  Ann Neurol. 2009;  66(5) 704-709
• 87 Eker A, Saka E, Dalmau J et al.. Testicular teratoma and anti-N-methyl-D-aspartate receptor-associated encephalitis.  J Neurol Neurosurg Psychiatry. 2008;  79(9) 1082-1083
• 88 Seki M, Suzuki S, Iizuka T et al.. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis.  J Neurol Neurosurg Psychiatry. 2008;  79(3) 324-326
• 89 Ishiura H, Matsuda S, Higashihara M et al.. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab.  Neurology. 2008;  71(23) 1921-1923
• 90 Shimazaki H, Ando Y, Nakano I, Dalmau J. Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus.  J Neurol Neurosurg Psychiatry. 2007;  78(3) 324-325
• 91 Iizuka T, Sakai F, Ide T et al.. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.  Neurology. 2008;  70(7) 504-511
• 92 Hughes E G, Peng X, Gleichman A J et al.. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis.  J Neurosci. 2010;  30(17) 5866-5875
• 93 Chalk C H, Murray N M, Newsom-Davis J, O'Neill J H, Spiro S G. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.  Neurology. 1990;  40(10) 1552-1556
• 94 Sillevis Smitt P, Grefkens J, de Leeuw B et al.. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy.  J Neurol. 2002;  249(6) 745-753
• 95 Graus F, Keime-Guibert F, Reñe R et al.. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.  Brain. 2001;  124(Pt 6) 1138-1148
• 96 Rojas I, Graus F, Keime-Guibert F et al.. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.  Neurology. 2000;  55(5) 713-715
• 97 Rojas-Marcos I, Graus F, Sanz G, Robledo A, Diaz-Espejo C. Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: case study.  Neuro-oncol. 2007;  9(1) 75-77
• 98 Hoffmann L A, Jarius S, Pellkofer H L et al.. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases.  J Neurol Neurosurg Psychiatry. 2008;  79(7) 767-773
• 99 David Y B, Warner E, Levitan M, Sutton D M, Malkin M G, Dalmau J O. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report.  Cancer. 1996;  78(10) 2153-2156
• 100 Rosenfeld M R, Dalmau J. Current therapies for paraneoplastic neurologic syndromes.  Curr Treat Options Neurol. 2003;  5(1) 69-77
• 101 Vernino S, O'Neill B P, Marks R S, O'Fallon J R, Kimmel D W. Immunomodulatory treatment trial for paraneoplastic neurological disorders.  Neuro-oncol. 2004;  6(1) 55-62
• 102 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle.  Muscle Nerve. 2000;  23(12) 1800-1818
• 103 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the peripheral nerves.  Curr Opin Neurol. 2005;  18(5) 598-603